A 12-Week, Phase 2 Study of Gemcabene in Hypercholesterolemia Patients on Stable Moderate and High-Intensity Statins

PHASE2CompletedINTERVENTIONAL
Enrollment

105

Participants

Timeline

Start Date

November 30, 2016

Primary Completion Date

June 30, 2017

Study Completion Date

August 31, 2017

Conditions
Hypercholesteremia
Interventions
DRUG

Gemcabene

Two 300 mg tablets and 1 placebo tablet administered orally, once daily for 12 weeks.

DRUG

Placebo

Three placebo tablets administered orally once daily for 12 weeks.

Trial Locations (24)

12553

Mid-Hudson Medical Research, New Windsor

14609

Rochester Clinical Research, Inc., Rochester

19446

Green and Seidner Family Practice Associates, Lansdale

32127

Progressive Medical Research, Port Orange

32216

Jacksonville Center for Clinical Research, Jacksonville

32751

Meridien Research, Inc., Maitland

33434

Excel Medical Clinical Trials, Boca Raton

33458

Health Awareness, Inc., Jupiter

33462

Atlantic Clinical Research Collaborative- Cardiology, Atlantis

33626

Varkey Medical, Tampa

35205

Central Research Associates, Inc., Birmingham

40213

L-MARC, Louisville

45219

Sterling Research Group, Ltd., Cincinnati

45236

Sentral Clinical Research Services, Cincinnati

45246

Sterling Research Group, Ltd., Cincinnati

46260

Midwest Institute for Clinical Research, Indianapolis

60201

Evanston Premier Healthcare Research, LLC, Evanston

77027

Associates in Medicine, Houston

77479

Sugar Lakes Family Practice, Sugar Land

78229

Diagnostics Research Grup, San Antonio

90057

National Research Institute, Los Angeles

90211

Westside Medical Associates of Los Angeles, Beverly Hills

90255

National Research Institute, Huntington Park

Unknown

National Research Institute, Richmond

Sponsors
All Listed Sponsors
lead

NeuroBo Pharmaceuticals Inc.

INDUSTRY